Cellebrite DI Ltd. has announced its financial results for the second quarter of 2025. The company reported a revenue increase of 18% year-over-year, reaching $113.3 million. Subscription revenue also saw a significant rise, increasing by 21% to $103.0 million. Cellebrite's Annual Recurring Revenue $(ARR)$ grew by 21% to $418.9 million. The company's GAAP net income for the quarter was $19.5 million, while the non-GAAP net income stood at $30.8 million. The adjusted EBITDA amounted to $27.9 million, with an adjusted EBITDA margin of 24.6%. Cellebrite's guidance for the third quarter of 2025 projects ARR to be between $435 million and $445 million, with an annual growth rate of 17% to 20%. Revenue is expected to range from $121 million to $126 million, reflecting an annual growth of 13% to 18%. The adjusted EBITDA for the third quarter is anticipated to be between $31 million and $34 million, with a margin of 26% to 27%. For the full year of 2025, Cellebrite forecasts ARR between $460 million and $475 million, with revenue expected to be in the range of $465 million to $475 million. The full-year adjusted EBITDA is projected to be between $118 million and $123 million, with a margin of 25% to 26%. The company also announced the appointment of Thomas E. Hogan as CEO. He expressed confidence in the company's ability to continue growing and supporting its customers in the public and private sectors, particularly in law enforcement, defense, and intelligence.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.